Selecta Biosciences (NASDAQ:SELB)‘s stock had its “buy” rating restated by investment analysts at Mizuho in a research note issued to investors on Monday. They presently have a $30.00 price objective on the stock. Mizuho’s target price suggests a potential upside of 430.97% from the company’s previous close.
The analysts wrote, “We hosted a doc call on 10/29 to discuss SEL-212. Our consultant noted some of the main potential advantages of SEL-212 vs. the standard of care including; 1) Improved treatment regimen with fewer infusions (1x/month) vs. a proposed Krystexxa combo (2x/month + daily or weekly anti-proliferative agent) and 2) Superior safety profile. Our consultant believes SEL-212 is ready for phase 3 given considerable amounts of data generated to date on treatment regimen and dosing along with clear objective measurements showing tophi mitigation and lowering of uric acid levels in a majority of patients. She argued that had the stopping rules not been as stringent in the phase 2 trial, the results may have looked better.””
SELB has been the topic of a number of other reports. Stifel Nicolaus assumed coverage on shares of Selecta Biosciences in a research report on Friday, September 14th. They set a “buy” rating and a $24.00 price target on the stock. BidaskClub upgraded shares of Selecta Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 9th. Zacks Investment Research lowered shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, August 29th. Canaccord Genuity restated a “buy” rating and set a $40.00 price target on shares of Selecta Biosciences in a research report on Wednesday, July 11th. Finally, Janney Montgomery Scott restated a “buy” rating on shares of Selecta Biosciences in a research report on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. Selecta Biosciences has an average rating of “Hold” and a consensus price target of $27.40.
Shares of NASDAQ SELB opened at $5.65 on Monday. Selecta Biosciences has a 52-week low of $4.74 and a 52-week high of $22.68. The stock has a market capitalization of $126.54 million, a PE ratio of -1.77 and a beta of 0.91. The company has a current ratio of 4.96, a quick ratio of 4.96 and a debt-to-equity ratio of 0.87.
Selecta Biosciences (NASDAQ:SELB) last announced its earnings results on Wednesday, August 8th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.16). Research analysts predict that Selecta Biosciences will post -3.07 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of SELB. Rhumbline Advisers boosted its holdings in Selecta Biosciences by 43.7% in the 2nd quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after purchasing an additional 5,103 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Selecta Biosciences by 37.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock valued at $447,000 after purchasing an additional 9,100 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Selecta Biosciences by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock valued at $626,000 after purchasing an additional 10,114 shares during the last quarter. Proxima Capital Management LLC acquired a new position in Selecta Biosciences in the 2nd quarter valued at about $1,075,000. Finally, Millennium Management LLC acquired a new position in Selecta Biosciences in the 2nd quarter valued at about $1,583,000. Institutional investors own 48.63% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Recommended Story: Stock Symbol
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.